Építés alatt – nem éles oldal
Belépés
FelfüggesztveFázis nélkül

Pelvic Nodes Ultra-Hypo vs Conventionally Fractionated IMRT With HDR Boost in Prostate Cancer.

A legfontosabb adatok

Ki végzi
CHU de Quebec-Universite Laval
Hol
Kanada11 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Felfüggesztve
Résztvevők
500 fő, tervezett
Kezdés
2022. szept. 1.
Várható befejezés
2035. dec.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Report and compare changes in a non-inferiority analysis of the International Prostate Symptom Score (I-PSS)
  • Report and compare changes in a non-inferiority analysis of the expanded prostate cancer index composite" (EPIC-26):
  • Report and compare changes in a non-inferiority analysis of the Sexual Health Inventory for Men (SHIM)
  • Report and compare changes in a non-inferiority analysis of the toxicities reported according to the Common Terminology Criteria for Adverse Events (CTCAE)
  • Report and compare the biochemical disease free survival (bDFS)
  • Report and compare the disease free survival (DFS)
  • Report and compare the metastase free survival (MFS)
  • Report and compare the overall survival (OS)
A regiszteradat frissítve
2025. szeptember 12.
Miért állt le
amendment to be done, adding 200 patients

Ki vehet részt

Életkor
18 év – 95 év
Nem
Csak férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 11 feltétel megnézéseKevesebb

Ki vehet részt

  • Histopathologically confirmed adenocarcinoma of the prostate
  • All clinical stages with lymph node involvement risk needing pelvis RT
  • Stage Mx or M0
  • Unfavorable Intermediate, high or very high-risk disease according to NCCN guidelines
  • Having the ability to give free and informed consent

Ki nem vehet részt

  • IPSS Score > 20 with alpha-blocking medication
  • Prior pelvic radiotherapy,
  • History of active collagenosis (Lupus, Scleroderma, Dermatomyositis)
  • Past history of Inflammatory Bowell Disease
  • Clinical stage M1
  • Bilateral hip prosthesis

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Randomized Phase III study, comparing pelvic ultra-hypo fractionated radiotherapy (UHF: 5Gy/fraction) to a standard or moderate hypo-fractionation (1.8-2.15Gy/fraction), both associated to an HDR prostate +/- adjacent seminal vesicles brachytherapy boost (HDR-BT)+ ADT according to NCCN guidelines. Considering that the calculated bio-equivalent doses to the tumor are similar for all treatment options, the UHF technique is deemed to be non-inferior to the standard approach. Treatment acceptability, tolerance and adverse events will be reported and compared for non-inferiority as the primary objective. Secondary objectives are biochemical control, metastasis-free, disease specific and overall survival.

A vizsgálat 2 csoportja

  • ultra hypo fractionation radiation therapy (UHF)A vizsgált kezelés

    5 radiation treatments (5 Gy per fraction) to the prostate, seminal vesicle and pelvic nodes given every other day over 2 weeks for a total of 25 Gy.

    Kezelés: Report and compare changes in a non-inferiority analysis of the International Prostate Symptom Score (I-PSS), Report and compare changes in a non-inferiority analysis of the expanded prostate cancer index composite" (EPIC-26):, Report and compare changes in a non-inferiority analysis of the Sexual Health Inventory for Men (SHIM), Report and compare changes in a non-inferiority analysis of the toxicities reported according to the Common Terminology Criteria for Adverse Events (CTCAE), Report and compare the biochemical disease free survival (bDFS), Report and compare the disease free survival (DFS), Report and compare the metastase free survival (MFS) és Report and compare the overall survival (OS)

  • standard of care fractionation (SOC)Már használt kezelés, összehasonlításként

    20-25 radiation treatments (range: 1,8 to 2,15 Gy per fraction) to the prostate, seminal vesicle and pelvic nodes given in 20-25 working day treatments over 4-5 weeks for a total of 43 Gy to 46 Gy.

    Kezelés: Report and compare changes in a non-inferiority analysis of the International Prostate Symptom Score (I-PSS), Report and compare changes in a non-inferiority analysis of the expanded prostate cancer index composite" (EPIC-26):, Report and compare changes in a non-inferiority analysis of the Sexual Health Inventory for Men (SHIM), Report and compare changes in a non-inferiority analysis of the toxicities reported according to the Common Terminology Criteria for Adverse Events (CTCAE), Report and compare the biochemical disease free survival (bDFS), Report and compare the disease free survival (DFS), Report and compare the metastase free survival (MFS) és Report and compare the overall survival (OS)

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Pelvic Nodes Ultra-Hypo Fractionated Versus Conventionally Fractionated IMRT With HDR Brachytherapy Boost in Prostate Cancer: A Collaborative Multi-institutional Non-inferiority Phase 3 Trial. (PCS-XI)
A regiszteradat frissítve
2025. szeptember 12.